Oligonucleotide CDMO Market
完整報告名稱與涵蓋範圍
Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA), Application (Therapeutic, Research, Diagnostics), End User (Pharma, Biotech), Region, Competition - Global Forecast to 2031
報告摘要
The oligonucleotide CDMO market is expected to reach USD 11.14 billion in 2031, up from USD 3.88 billion in 2026, at a CAGR of 23.5% over the forecast period. The oligonucleotide CDMO market is expanding as pharmaceutical and biotechnology companies increasingly outsource development and manufacturing to support growing oligonucleotide pipelines. Growing CDMO partnerships to enable scalability are driving demand for process development, synthesis, purification, analytical testing, and GMP manufacturing as programs advance toward clinical and commercial stages. Sponsors are increasingly seeking CDMOs with flexible capacity and integrated capabilities to support development through commercial manufacturing. However, the complexities of therapeutic oligonucleotide manufacturing remain a key restraint. Longer sequences, chemical modifications, and conjugation can increase synthesis and purification challenges. Maintaining consistent quality during scale-up also requires specialized equipment, validated processes, and skilled personnel. Consequently, CDMOs with scalable infrastructure and strong analytical capabilities are better positioned to support complex oligonucleotide programs.
“Antisense oligonucleotides segment is expected to grow at the highest CAGR during the forecast period”
The antisense oligonucleotide (ASO) segment is projected to grow at the highest CAGR in the oligonucleotide CDMO market, driven by expanding development of ASO-based therapeutics and increased outsourcing of manufacturing. ASO programs require specialized synthesis, purification, analytical testing, and GMP manufacturing capabilities. The advancement of ASO candidates through clinical development is increasing demand for scalable and reliable CDMO services. Rising molecular complexity is also prompting pharmaceutical and biotechnology companies to outsource manufacturing to specialized providers. These factors are expected to strengthen demand for oligonucleotide CDMO services supporting ASO development over the forecast period.
“Therapeutic applications segment to grow fastest”
The therapeutic applications segment is projected to grow at the highest CAGR in the oligonucleotide CDMO market, driven by expanding development of oligonucleotide-based therapeutics and increased outsourcing of manufacturing. Therapeutic programs require specialized services for synthesis, purification, analytical testing, and GMP manufacturing. The advancement of ASO, siRNA, and other oligonucleotide candidates through clinical development is increasing demand for scalable, regulatory-compliant manufacturing. Rising molecular complexity is further encouraging pharmaceutical and biotechnology companies to rely on specialized CDMOs. These factors are expected to strengthen demand for CDMO services supporting therapeutic applications during the forecast period.
“US is expected to grow at the highest CAGR during the forecast period”
The US is expected to post the highest CAGR in the oligonucleotide CDMO market, driven by a strong concentration of pharmaceutical and biotechnology companies with active oligonucleotide development pipelines. Established CDMO infrastructure and specialized capabilities in oligonucleotide synthesis, purification, analytical testing, and GMP manufacturing further support market growth. Rising demand for clinical and commercial manufacturing capacity is also strengthening outsourcing activity. Advancements in ASO, siRNA, and other oligonucleotide programs are driving demand for scalable manufacturing and specialized process development. These factors are expected to support continued expansion of the US oligonucleotide CDMO market over the forecast period.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side – 70% and Demand Side– 30%
• By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
• By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5%
Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), WuXi AppTec (China), Maravai LifeSciences (US), Lonza (Switzerland), Eurofins Scientific (Luxembourg), Danaher Corporation (US), GenScript (US), Syngene International Limited (India), Ajinomoto Co., Inc. (Japan), EUROAPI (France), ST Pharm (South Korea), Kaneka Corporation (Japan), PolyPeptide Group (Switzerland), Aurigene Pharmaceutical Services Ltd. (India), BioSpring (Germany), Nippon Shokubai Co., Ltd. (Japan), LGC Biosearch Technologies (UK), Oligo Factory (US), Corden Pharma (Switzerland), Bio-Synthesis, Inc. (US), Microsynth (Switzerland), Synoligo Biotechnologies, Inc. (US), Hongene Biotech Corporation (China), Sylentis, S.A. (Spain), Creative Biogene (US), Nitto Avecia (US), and NJ Bio, Inc. (US) are key companies providing oligonucleotide CDMO services.
Research Coverage
This research report categorizes the oligonucleotide CDMO market by service type (contract manufacturing {commercial stage, clinical stage}, contract development, and other services {analytical testing, analytical method development & validation, and standalone fill-finish services}), by type (antisense oligonucleotides, small interfering RNA, and other oligonucleotides), by application (therapeutic applications, research applications, and diagnostic applications), by end user (pharmaceutical & biotechnology companies, diagnostic companies, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report’s scope encompasses detailed information on the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the oligonucleotide CDMO market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, service portfolios, key strategies, service expansions, acquisitions, and recent developments related to the oligonucleotide CDMO market. This report also includes a competitive analysis of emerging startups in the oligonucleotide CDMO industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
• Analysis of key drivers (Growing demand for pre-clinical-to-commercial oligo CDMOs, Increase in CDMO partnerships for scalability, Increasing focus on precision/personalized medicine), restraints (Complexities associated with therapeutic oligonucleotide manufacturing), opportunities (Increasing use of oligos in CRISPR-Cas9 applications, Growing demand for complex and modified oligonucleotides), and challenges (Lack of sustainable supply chain, Limited scalability of GMP oligonucleotide synthesis) influencing the market growth
• Service Development/Innovation: Detailed insights into newly launched services and innovations in the oligonucleotide CDMO market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and services of leading players, Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), WuXi AppTec (China), and ST Pharm (South Korea), among others, for the oligonucleotide CDMO market.
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS & EXCLUSIONS 32
1.3 STUDY SCOPE 33
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 33
1.3.2 YEARS CONSIDERED 34
1.3.3 CURRENCY CONSIDERED 34
1.4 STAKEHOLDERS 34
1.5 SUMMARY OF CHANGES 35
2 EXECUTIVE SUMMARY 36
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 36
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 37
2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDES CDMO MARKET 38
2.4 HIGH-GROWTH SEGMENTS 39
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 40
3 PREMIUM INSIGHTS 41
3.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW 41
3.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE 42
3.3 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 43
3.4 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY SERVICE TYPE, 2026 VS. 2031 44
4 MARKET OVERVIEW 45
4.1 INTRODUCTION 45
4.2 MARKET DYNAMICS 45
4.2.1 DRIVERS 46
4.2.1.1 Growing demand for Pre-Clinical-to-Commercial oligo CDMOs 46
4.2.1.2 Increase in CDMO partnerships for scalability 47
4.2.1.3 Increasing focus on precision/personalized medicine 47
4.2.2 RESTRAINTS 48
4.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing 48
4.2.3 OPPORTUNITIES 48
4.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications 48
4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases 49
4.2.4 CHALLENGES 49
4.2.4.1 Lack of sustainable supply chain 49
4.2.4.2 Limited scalability of GMP oligonucleotide synthesis 50
4.3 UNMET NEEDS AND WHITE SPACES 50
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 51
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 51
5 INDUSTRY TRENDS 53
5.1 PORTER’S FIVE FORCES ANALYSIS 53
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 54
5.1.2 BARGAINING POWER OF SUPPLIERS 54
5.1.3 BARGAINING POWER OF BUYERS 55
5.1.4 THREAT OF SUBSTITUTES 55
5.1.5 THREAT OF NEW ENTRANTS 55
5.2 MACROECONOMIC OUTLOOK 55
5.2.1 INTRODUCTION 55
5.2.2 GDP TRENDS AND FORECAST 56
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 57
5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY 57
5.3 VALUE CHAIN ANALYSIS 58
5.4 ECOSYSTEM ANALYSIS 59
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 61
5.5 KEY CONFERENCES & EVENTS, 2026–2027 62
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63
5.7 INVESTMENT & FUNDING SCENARIO 64
5.8 IMPACT OF 2025 US TARIFF ON OLIGONUCLEOTIDE CDMO MARKET 65
5.8.1 INTRODUCTION 65
5.8.2 KEY TARIFF RATES 65
5.8.3 PRICE IMPACT ANALYSIS 66
5.8.4 IMPACT ON COUNTRY/REGION 67
5.8.4.1 US 67
5.8.4.2 Europe 67
5.8.4.3 Asia Pacific 68
5.8.5 IMPACT ON END-USE INDUSTRIES 69
5.8.5.1 Pharmaceutical & Biotechnology Companies 69
5.8.5.2 Diagnostic companies 69
5.8.5.3 Other end users 70
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 71
6.1 TECHNOLOGY ANALYSIS 71
6.1.1 KEY TECHNOLOGIES 71
6.1.1.1 Process technologies 71
6.1.1.1.1 Solid-phase synthesis 71
6.1.1.1.2 Liquid-phase synthesis 72
6.1.1.1.3 Enzymatic phase synthesis 72
6.1.1.2 Purification, analysis, and quality control technologies 72
6.1.1.2.1 Affinity chromatography 72
6.1.1.2.2 Tangential flow filtration (tff) & ultrafiltration 73
6.1.2 COMPLEMENTARY TECHNOLOGIES 73
6.1.2.1 Polymerase chain reaction (PCR) 73
6.1.2.2 Next-generation sequencing (NGS) 74
6.1.2.3 Microarray technology/hybridization-based assays 74
6.1.3 ADJACENT TECHNOLOGIES 74
6.1.3.1 Galnac conjugation/Antibody–oligonucleotide conjugation 74
6.1.3.2 Lipid nanoparticle (LNP) encapsulation 75
6.2 TECHNOLOGY ROADMAP 75
6.3 FUTURE APPLICATIONS 76
6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET 76
6.4.1 TOP USE CASES AND MARKET POTENTIAL 77
6.4.2 BEST PRACTICES IN AI-ENABLED OLIGONUCLEOTIDE CDMO WORKFLOWS 78
6.4.3 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET 78
6.4.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 78
6.4.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES 79
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 80
7.1 REGIONAL REGULATIONS AND COMPLIANCE 80
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
7.1.2 INDUSTRY STANDARDS 83
7.1.2.1 North America 83
7.1.2.2 Europe 83
7.1.2.3 Asia Pacific 84
7.1.2.4 Rest of the World 84
7.2 SUSTAINABILITY INITIATIVES 85
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 85
7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS 86
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 88
8.1 DECISION-MAKING PROCESS 88
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 88
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 88
8.2.2 KEY BUYING CRITERIA, BY END USER 89
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 90
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 91
9 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE 92
9.1 INTRODUCTION 93
9.2 CONTRACT MANUFACTURING 93
9.2.1 COMMERCIAL STAGE 97
9.2.1.1 Advancing oligonucleotide therapies and demand for reliable commercial-scale GMP supply are driving growth in commercial-stage services 97
9.2.2 CLINICAL STAGE 100
9.2.2.1 Advancing clinical pipelines and demand for specialized scalable manufacturing are driving growth in clinical-stage services 100
9.3 CONTRACT DEVELOPMENT 104
9.3.1 INCREASINGLY COMPLEX OLIGONUCLEOTIDE PIPELINES AND DEMAND FOR OPTIMIZED CLINICAL MANUFACTURING PROCESSES ARE DRIVING CONTRACT DEVELOPMENT GROWTH 104
9.4 OTHER SERVICES 107
9.4.1 INCREASING MOLECULAR COMPLEXITY AND DEMAND FOR INTEGRATED ANALYTICAL AND DRUG-PRODUCT SUPPORT ARE DRIVING GROWTH IN OTHER SERVICES 107
10 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION 111
10.1 INTRODUCTION 112
10.2 THERAPEUTIC APPLICATIONS 112
10.2.1 EXPANDING THERAPEUTIC APPLICATIONS AND ADVANCING OLIGONUCLEOTIDE PIPELINES ARE DRIVING DEMAND FOR SPECIALIZED CDMO SERVICES. 112
10.3 RESEARCH APPLICATIONS 116
10.3.1 EXPANDING GENOMICS, SEQUENCING, CRISPR RESEARCH, AND OUTSOURCED CUSTOM SYNTHESIS DRIVE GROWTH 116
10.4 DIAGNOSTIC APPLICATIONS 119
10.4.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION ONCOLOGY DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE MANUFACTURING 119
11 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE 123
11.1 INTRODUCTION 124
11.2 ANTISENSE OLIGONUCLEOTIDE (ASO) 124
11.2.1 ADVANCING ASO PIPELINES AND INCREASING DEMAND FOR SCALABLE GMP MANUFACTURING ARE DRIVING GROWTH 124
11.3 SMALL INTERFERING RNA (SIRNA) 128
11.3.1 EXPANDING SIRNA PIPELINES AND INCREASING DEMAND FOR SPECIALIZED GMP MANUFACTURING ARE DRIVING GROWTH IN THE MARKET. 128
11.4 OTHER OLIGONUCLEOTIDES 131
11.4.1 EXPANDING CRISPR AND TARGETED APTAMER APPLICATIONS DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE CDMO CAPABILITIES 131
12 OLIGONUCLEOTIDE CDMO MARKET, BY END USER 135
12.1 INTRODUCTION 136
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 136
12.2.1 EXPANDING NUCLEIC ACID PIPELINES AND INCREASING OUTSOURCING DRIVE PHARMACEUTICAL AND BIOTECHNOLOGY DEMAND FOR CDMO SERVICES 136
12.3 DIAGNOSTIC COMPANIES 140
12.3.1 RISING MOLECULAR TESTING AND DEMAND FOR COMPLIANT CUSTOM OLIGOS DRIVE DIAGNOSTIC OUTSOURCING 140
12.4 OTHER END USERS 143
13 OLIGONUCLEOTIDE CDMO MARKET, BY REGION 147
13.1 INTRODUCTION 148
13.2 NORTH AMERICA 148
13.2.1 US 152
13.2.1.1 Expanding domestic GMP capacity and increasing outsourcing are driving US oligonucleotide CDMO growth. 152
13.2.2 CANADA 154
13.2.2.1 Integrated North American manufacturing networks and growing outsourcing demand are supporting Canada’s oligonucleotide CDMO market 154
13.3 EUROPE 156
13.3.1 GERMANY 158
13.3.1.1 Expanding GMP capacity and integrated oligonucleotide partnerships are driving Germany’s market growth 158
13.3.2 UK 160
13.3.2.1 Strengthening domestic nucleic-acid infrastructure and growing outsourcing demand are driving UK oligonucleotide CDMO growth 160
13.3.3 FRANCE 162
13.3.3.1 Strengthening nucleic-acid capabilities and growing outsourcing demand are driving France’s oligonucleotide CDMO market 162
13.3.4 ITALY 164
13.3.4.1 Specialized oligonucleotide infrastructure and growing demand for integrated development services are supporting Italy’s market growth 164
13.3.5 SPAIN 166
13.3.5.1 Expanding domestic manufacturing infrastructure and institutional support for therapeutic oligonucleotides are driving Spain’s market growth 166
13.3.6 REST OF EUROPE 168
13.4 ASIA PACIFIC 170
13.4.1 CHINA 173
13.4.1.1 Expanding integrated manufacturing capacity and strengthening domestic oligonucleotide supply chains are driving China’s market growth 173
13.4.2 JAPAN 176
13.4.2.1 Advanced manufacturing capabilities and rising demand for complex oligonucleotide therapeutics are driving Japan’s market growth 176
13.4.3 INDIA 178
13.4.3.1 Expanding GMP infrastructure and global outsourcing are driving India’s oligonucleotide CDMO market 178
13.4.4 AUSTRALIA 180
13.4.4.1 Expanding domestic manufacturing and growing biopharmaceutical outsourcing are supporting Australia’s oligonucleotide CDMO market 180
13.4.5 SOUTH KOREA 182
13.4.5.1 Synthetic biology, organoid-based screening, and AI-enabled discovery to support market growth 182
13.4.6 REST OF ASIA PACIFIC 184
13.5 LATIN AMERICA 186
13.5.1 BRAZIL 188
13.5.1.1 Infectious-disease research, shared protein-production infrastructure, and vaccine innovation to drive market 188
13.5.2 MEXICO 190
13.5.2.1 Nearshoring and expanding regional manufacturing capabilities are supporting Mexico’s oligonucleotide CDMO market 190
13.5.3 REST OF LATIN AMERICA 192
13.6 MIDDLE EAST 194
13.6.1 GCC 197
13.6.1.1 Saudi Arabia 199
13.6.1.1.1 Biotechnology localization and expanding genomic medicine capabilities are driving Saudi Arabia’s oligonucleotide CDMO market 199
13.6.1.2 UAE 201
13.6.1.2.1 Growing biopharmaceutical activity and need for localized advanced-therapy manufacturing are creating opportunities for UAE’s oligonucleotide CDMO services 201
13.6.1.3 Rest of GCC Countries 203
13.6.2 REST OF MIDDLE EAST 205
13.7 AFRICA 207
13.7.1 GROWING GENOMICS ACTIVITY AND LIMITED LOCAL MANUFACTURING CAPACITY ARE CREATING OPPORTUNITIES FOR OLIGONUCLEOTIDE CDMO SERVICES ACROSS AFRICA 207
14 COMPETITIVE LANDSCAPE 210
14.1 INTRODUCTION 210
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 210
14.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023–2026 210
14.3 REVENUE ANALYSIS 212
14.4 MARKET SHARE ANALYSIS 213
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE CDMO MARKET), 2025 216
14.5.1 STARS 216
14.5.2 EMERGING LEADERS 216
14.5.3 PERVASIVE PLAYERS 217
14.5.4 PARTICIPANTS 217
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 223
14.6.1 PROGRESSIVE COMPANIES 223
14.6.2 RESPONSIVE COMPANIES 223
14.6.3 DYNAMIC COMPANIES 223
14.6.4 STARTING BLOCKS 223
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 225
14.7 COMPETITIVE SCENARIO 226
14.7.1 PRODUCT APPROVALS 226
14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 230
14.9 COMPANY VALUATION AND FINANCIAL METRICS 231
14.9.1 COMPANY VALUATION AND FINANCIAL METRICS FOR OLIGONUCLEOTIDE CDMO PLAYERS 231
15 COMPANY PROFILES 232
15.1 KEY PLAYERS 232
15.1.1 BACHEM INC. 232
15.1.1.1 Business overview 232
15.1.1.2 Services offered 233
15.1.1.3 Recent developments 234
15.1.1.3.1 Product/Service launches 234
15.1.1.3.2 Expansions 234
15.1.1.4 MnM view 234
15.1.1.4.1 Key strengths 234
15.1.1.4.2 Strategic choices 235
15.1.1.4.3 Weaknesses and competitive threats 235
15.1.2 THERMO FISHER SCIENTIFIC INC. 236
15.1.2.1 Business overview 236
15.1.2.2 Services offered 237
15.1.2.3 Recent developments 238
15.1.2.3.1 Product/Service launches 238
15.1.2.3.2 Expansions 238
15.1.2.4 MnM view 238
15.1.2.4.1 Key strengths 238
15.1.2.4.2 Strategic choices 239
15.1.2.4.3 Weaknesses and competitive threats 239
15.1.3 AGILENT TECHNOLOGIES, INC. 240
15.1.3.1 Business overview 240
15.1.3.2 Services offered 241
15.1.3.3 Recent developments 242
15.1.3.3.1 Product/Service launches 242
15.1.3.3.2 Deals 242
15.1.3.3.3 Expansions 243
15.1.3.4 MnM view 243
15.1.3.4.1 Key strengths 243
15.1.3.4.2 Strategic choices 243
15.1.3.4.3 Weaknesses and competitive threats 243
15.1.4 WUXI APPTEC 244
15.1.4.1 Business overview 244
15.1.4.2 Services offered 245
15.1.4.3 Recent developments 246
15.1.4.3.1 Expansions 246
15.1.4.4 MnM view 246
15.1.4.4.1 Key strengths/Right to win 246
15.1.4.4.2 Strategic choices made 246
15.1.4.4.3 Weaknesses and competitive threats 246
15.1.5 MARAVAI LIFESCIENCES 247
15.1.5.1 Business overview 247
15.1.5.2 Services offered 248
15.1.5.3 Recent developments 249
15.1.5.3.1 Deals 249
15.1.6 LONZA 250
15.1.6.1 Business overview 250
15.1.6.2 Services offered 251
15.1.6.3 Recent developments 252
15.1.6.3.1 Deals 252
15.1.6.3.2 Expansions 252
15.1.7 EUROFINS SCIENTIFIC 253
15.1.7.1 Business overview 253
15.1.7.2 Services offered 254
15.1.7.3 Recent developments 255
15.1.7.3.1 Expansions 255
15.1.8 DANAHER CORPORATION 256
15.1.8.1 Business overview 256
15.1.8.2 Services offered 257
15.1.8.3 Recent developments 258
15.1.8.3.1 Expansions 258
15.1.8.3.2 Other Developments 258
15.1.9 GENSCRIPT 259
15.1.9.1 Business overview 259
15.1.9.2 Services offered 260
15.1.9.3 Recent developments 261
15.1.9.3.1 Expansions 261
15.1.10 SYNGENE INTERNATIONAL LIMITED 262
15.1.10.1 Business overview 262
15.1.10.2 Services offered 263
15.1.10.3 Recent developments 264
15.1.10.3.1 Product/Service launches 264
15.1.10.3.2 Expansions 264
15.1.11 EUROAPI 265
15.1.11.1 Business overview 265
15.1.11.2 Services offered 266
15.1.11.3 Recent developments 267
15.1.11.3.1 Deals 267
15.1.11.3.2 Expansions 267
15.1.12 AJINOMOTO CO., INC. 268
15.1.12.1 Business overview 268
15.1.12.2 Services offered 269
15.1.12.3 Recent developments 269
15.1.12.3.1 Expansions 269
15.1.12.3.2 Deals 269
15.1.13 ST PHARM 270
15.1.13.1 Business overview 270
15.1.13.2 Services offered 271
15.1.13.3 Recent developments 271
15.1.13.3.1 Expansions 271
15.1.13.3.2 Deals 271
15.1.13.4 MnM view 272
15.1.13.4.1 Key strengths 272
15.1.13.4.2 Strategic choices 272
15.1.13.4.3 Weaknesses and competitive threats 272
15.1.14 KANEKA CORPORATION 273
15.1.14.1 Business overview 273
15.1.14.2 Services offered 275
15.1.15 POLYPEPTIDE GROUP 276
15.1.15.1 Business overview 276
15.1.15.2 Services offered 277
15.1.15.3 Recent developments 277
15.1.15.3.1 Expansions 277
15.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD. 278
15.1.16.1 Business overview 278
15.1.16.2 Services offered 278
15.1.17 BIOSPRING 279
15.1.17.1 Business overview 279
15.1.17.2 Services offered 279
15.1.17.3 Recent developments 280
15.1.17.3.1 Service approvals 280
15.1.17.3.2 Expansions 280
15.1.18 NIPPON SHOKUBAI CO., LTD. 281
15.1.18.1 Business overview 281
15.1.18.2 Services offered 282
15.1.18.3 Recent developments 283
15.1.18.3.1 Service launch 283
15.1.18.3.2 Expansions 283
15.1.19 LGC BIOSEARCH TECHNOLOGIES 284
15.1.19.1 Business overview 284
15.1.19.2 Services offered 285
15.1.19.3 Recent developments 286
15.1.19.3.1 Service launch 286
15.1.19.3.2 Deals 286
15.1.19.3.3 Expansions 287
15.2 OTHER PLAYERS 288
15.2.1 OLIGO FACTORY 288
15.2.2 CORDEN PHARMA 288
15.2.3 BIO-SYNTHESIS, INC. 289
15.2.4 MICROSYNTH 289
15.2.5 SYNOLIGO BIOTECHNOLOGIES, INC. 290
15.2.6 HONGENE BIOTECH CORPORATION 290
15.2.7 SYLENTIS, S.A. 291
15.2.8 CREATIVE BIOGENE 291
15.2.9 NITTO AVECIA 292
15.2.10 NJ BIO, INC. 293
16 RESEARCH METHODOLOGY 294
16.1 RESEARCH DATA 294
16.1.1 SECONDARY DATA 295
16.1.1.1 Key data from secondary sources 295
16.1.2 PRIMARY DATA 296
16.1.2.1 Key data from primary sources 296
16.1.2.2 Key primary participants 296
16.1.2.3 Breakdown of primary interviews 297
16.1.2.4 Key industry insights 298
16.2 MARKET SIZE ESTIMATION 299
16.2.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025 299
16.2.2 SEGMENTAL MARKET SIZE ESTIMATION 302
16.3 MARKET GROWTH RATE PROJECTIONS 303
16.4 DATA TRIANGULATION 305
16.5 FACTOR ANALYSIS 306
16.6 RESEARCH ASSUMPTIONS 306
16.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 307
17 APPENDIX 308
17.1 DISCUSSION GUIDE 308
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 312
17.3 CUSTOMIZATION OPTIONS 314
17.4 RELATED REPORTS 314
17.5 AUTHOR DETAILS 315
圖表清單 List of Tables & Figures
TABLE 1 OLIGONUCLEOTIDE CDMO MARKET: INCLUSIONS AND EXCLUSIONS 32
TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS 46
TABLE 3 OLIGONUCLEOTIDE CDMO MARKET: PORTER’S FIVE FORCES 53
TABLE 4 OLIGONUCLEOTIDE CDMO MARKET: ROLE OF PLAYERS IN ECOSYSTEM 61
TABLE 5 OLIGONUCLEOTIDE CDMO MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–JUNE 2027 62
TABLE 6 RECIPROCAL TARIFF RATES ADJUSTED BY US 65
TABLE 7 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET 78
TABLE 8 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES IN OLIGONUCLEOTIDE CDMO MARKET 79
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 14 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE 89
TABLE 15 KEY BUYING CRITERIA, BY END USER 89
TABLE 16 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 93
TABLE 17 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING,
BY TYPE, 2024–2031 (USD MILLION) 94
TABLE 18 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING,
BY REGION, 2024–2031 (USD MILLION) 94
TABLE 19 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 94
TABLE 20 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 95
TABLE 21 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 95
TABLE 22 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 96
TABLE 23 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 96
TABLE 24 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 96
TABLE 25 OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 97
TABLE 26 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 98
TABLE 27 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 98
TABLE 28 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 99
TABLE 29 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 99
TABLE 30 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 100
TABLE 31 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 100
TABLE 32 OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 101
TABLE 33 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 101
TABLE 34 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 102
TABLE 35 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 102
TABLE 36 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 103
TABLE 37 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 103
TABLE 38 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 103
TABLE 39 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 104
TABLE 40 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 105
TABLE 41 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 105
TABLE 42 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 106
TABLE 43 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 106
TABLE 44 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 107
TABLE 45 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 107
TABLE 46 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION,
2024–2031 (USD MILLION) 108
TABLE 47 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 108
TABLE 48 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 49 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 50 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 51 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY REGION, 2024–2031 (USD MILLION) 110
TABLE 52 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY REGION, 2024–2031 (USD MILLION) 110
TABLE 53 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 112
TABLE 54 OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 113
TABLE 55 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 113
TABLE 56 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 114
TABLE 57 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 114
TABLE 58 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 59 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 115
TABLE 60 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 115
TABLE 61 OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 116
TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 63 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 66 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 67 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 68 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 120
TABLE 69 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 70 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 71 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 72 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 73 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 74 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 75 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 124
TABLE 76 OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION,
2024–2031 (USD MILLION) 125
TABLE 77 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO,
BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 78 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 79 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 80 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 81 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION,
2024–2031 (USD MILLION) 127
TABLE 82 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION,
2024–2031 (USD MILLION) 127
TABLE 83 OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION,
2024–2031 (USD MILLION) 128
TABLE 84 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 85 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY,
2024–2031 (USD MILLION) 129
TABLE 86 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 87 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 88 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION,
2024–2031 (USD MILLION) 131
TABLE 89 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA,
BY REGION, 2024–2031 (USD MILLION) 131
TABLE 90 OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION,
2024–2031 (USD MILLION) 132
TABLE 91 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 92 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 93 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 94 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 95 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS,
BY REGION, 2024–2031 (USD MILLION) 134
TABLE 96 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS,
BY REGION, 2024–2031 (USD MILLION) 134
TABLE 97 OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION) 136
TABLE 98 OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 99 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 100 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 101 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 102 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 103 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 104 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 105 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 106 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 107 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES,
BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 108 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 109 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 110 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 111 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 112 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 144
TABLE 113 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 114 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 115 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 116 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 117 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY REGION, 2024–2031 (USD MILLION) 146
TABLE 118 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY REGION, 2024–2031 (USD MILLION) 146
TABLE 119 OLIGONUCLEOTIDE CDMO MARKET, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 120 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 121 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 150
TABLE 122 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 150
TABLE 123 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 150
TABLE 124 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 151
TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 151
TABLE 126 US: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 152
TABLE 127 US: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 152
TABLE 128 US: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 153
TABLE 129 US: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 153
TABLE 130 US: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 153
TABLE 131 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 154
TABLE 132 CANADA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 155
TABLE 133 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 155
TABLE 134 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 155
TABLE 135 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 156
TABLE 136 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 156
TABLE 137 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 157
TABLE 138 EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 157
TABLE 139 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 157
TABLE 140 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 158
TABLE 141 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 158
TABLE 142 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 159
TABLE 143 GERMANY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 159
TABLE 144 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 159
TABLE 145 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 160
TABLE 146 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 160
TABLE 147 UK: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 161
TABLE 148 UK: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 161
TABLE 149 UK: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 161
TABLE 150 UK: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 162
TABLE 151 UK: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 162
TABLE 152 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 163
TABLE 153 FRANCE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 163
TABLE 154 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 163
TABLE 155 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 164
TABLE 156 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 164
TABLE 157 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 165
TABLE 158 ITALY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 165
TABLE 159 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 165
TABLE 160 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 166
TABLE 161 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 166
TABLE 162 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 167
TABLE 163 SPAIN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 167
TABLE 164 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 167
TABLE 165 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 168
TABLE 166 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 168
TABLE 167 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 169
TABLE 168 REST OF EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 169
TABLE 169 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 169
TABLE 170 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 170
TABLE 171 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 170
TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 173 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 172
TABLE 174 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 172
TABLE 175 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 172
TABLE 176 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 173
TABLE 177 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 173
TABLE 178 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 174
TABLE 179 CHINA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 174
TABLE 180 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 175
TABLE 181 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 175
TABLE 182 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 175
TABLE 183 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 176
TABLE 184 JAPAN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 176
TABLE 185 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 177
TABLE 186 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 177
TABLE 187 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 177
TABLE 188 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 178
TABLE 189 INDIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 178
TABLE 190 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 179
TABLE 191 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 179
TABLE 192 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 179
TABLE 193 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 180
TABLE 194 AUSTRALIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 180
TABLE 195 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 181
TABLE 196 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 181
TABLE 197 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 181
TABLE 198 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 182
TABLE 199 SOUTH KOREA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 182
TABLE 200 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 183
TABLE 201 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 183
TABLE 202 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 183
TABLE 203 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 184
TABLE 204 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 184
TABLE 205 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 185
TABLE 206 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 185
TABLE 207 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 185
TABLE 208 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 186
TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 186
TABLE 210 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 187
TABLE 211 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 187
TABLE 212 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 187
TABLE 213 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 188
TABLE 214 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 189
TABLE 215 BRAZIL: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 189
TABLE 216 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 189
TABLE 217 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 190
TABLE 218 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 190
TABLE 219 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 191
TABLE 220 MEXICO: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 191
TABLE 221 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 222 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 192
TABLE 223 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 192
TABLE 224 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 193
TABLE 225 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 193
TABLE 226 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,
BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 227 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 194
TABLE 228 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,
BY END USER, 2024–2031 (USD MILLION) 194
TABLE 229 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 195
TABLE 230 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 195
TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 195
TABLE 232 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 196
TABLE 233 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 196
TABLE 234 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 196
TABLE 235 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 236 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 197
TABLE 237 GCC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 198
TABLE 238 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 198
TABLE 239 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 198
TABLE 240 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 199
TABLE 241 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 199
TABLE 242 SAUDI ARABIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 200
TABLE 243 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 200
TABLE 244 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 200
TABLE 245 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 201
TABLE 246 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 201
TABLE 247 UAE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 202
TABLE 248 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 202
TABLE 249 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 202
TABLE 250 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 203
TABLE 251 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 203
TABLE 252 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 204
TABLE 253 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,
BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 254 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 204
TABLE 255 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,
BY END USER, 2024–2031 (USD MILLION) 205
TABLE 256 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 205
TABLE 257 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 206
TABLE 258 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 206
TABLE 259 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 206
TABLE 260 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 207
TABLE 261 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 208
TABLE 262 AFRICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 208
TABLE 263 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 264 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 209
TABLE 265 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 209
TABLE 266 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023–2026 211
TABLE 267 OLIGONUCLEOTIDE CDMO MARKET: DEGREE OF COMPETITION 214
TABLE 268 OLIGONUCLEOTIDE CDMO MARKET: REGIONAL FOOTPRINT 219
TABLE 269 OLIGONUCLEOTIDE CDMO MARKET: SERVICE TYPE FOOTPRINT 220
TABLE 270 OLIGONUCLEOTIDE CDMO MARKET: TYPE FOOTPRINT 221
TABLE 271 OLIGONUCLEOTIDE CDMO MARKET: APPLICATION FOOTPRINT 222
TABLE 272 DETAILED LIST OF KEY STARTUPS/SMES 225
TABLE 273 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 226
TABLE 274 OLIGONUCLEOTIDE CDMO MARKET: SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 226
TABLE 275 OLIGONUCLEOTIDE CDMO MARKET: DEALS, JANUARY 2023-JULY 2026 227
TABLE 276 OLIGONUCLEOTIDE CDMO MARKET: EXPANSIONS, JANUARY 2023-JULY 2026 229
TABLE 277 BACHEM INC.: COMPANY OVERVIEW 232
TABLE 278 BACHEM INC.: SERVICES OFFERED 233
TABLE 279 BACHEM INC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026 234
TABLE 280 BACHEM INC.: EXPANSIONS, JANUARY 2023–JULY 2026 234
TABLE 281 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 236
TABLE 282 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 237
TABLE 283 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 238
TABLE 284 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–JULY 2026 238
TABLE 285 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 240
TABLE 286 AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED 241
TABLE 287 AGILENT TECHNOLOGIES, INC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026 242
TABLE 288 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JULY 2026 242
TABLE 289 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023–JULY 2026 243
TABLE 290 WUXI APPTEC: COMPANY OVERVIEW 244
TABLE 291 WUXI APPTEC: SERVICES OFFERED 245
TABLE 292 WUXI APPTEC: EXPANSIONS, JANUARY 2023–JULY 2026 246
TABLE 293 MARAVAI LIFESCIENCES: COMPANY OVERVIEW 247
TABLE 294 MARAVAI LIFESCIENCES: SERVICES OFFERED 248
TABLE 295 MARAVAI LIFESCIENCES: DEALS, JANUARY 2023–JULY 2026 249
TABLE 296 LONZA: COMPANY OVERVIEW 250
TABLE 297 LONZA: SERVICES OFFERED 251
TABLE 298 LONZA: DEALS, JANUARY 2023–JULY 2026 252
TABLE 299 LONZA: EXPANSIONS, JANUARY 2023–JULY 2026 252
TABLE 300 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 253
TABLE 301 EUROFINS SCIENTIFIC: SERVICES OFFERED 254
TABLE 302 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023–JULY 2026 255
TABLE 303 DANAHER CORPORATION: COMPANY OVERVIEW 256
TABLE 304 DANAHER CORPORATION: SERVICES OFFERED 257
TABLE 305 DANAHER CORPORATION: EXPANSIONS, JANUARY 2023–JULY 2026 258
TABLE 306 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 258
TABLE 307 GENSCRIPT: COMPANY OVERVIEW 259
TABLE 308 GENSCRIPT: SERVICES OFFERED 260
TABLE 309 GENSCRIPT: EXPANSIONS, JANUARY 2023–JULY 2026 261
TABLE 310 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW 262
TABLE 311 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED 263
TABLE 312 SYNGENE INTERNATIONAL LIMITED: SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 264
TABLE 313 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2023–JULY 2026 264
TABLE 314 EUROAPI: COMPANY OVERVIEW 265
TABLE 315 EUROAPI: SERVICES OFFERED 266
TABLE 316 EUROAPI: DEALS, JANUARY 2023–JULY 2026 267
TABLE 317 EUROAPI: EXPANSIONS, JANUARY 2023–JULY 2026 267
TABLE 318 AJINOMOTO CO., INC.: COMPANY OVERVIEW 268
TABLE 319 AJINOMOTO CO., INC.: SERVICES OFFERED 269
TABLE 320 AJINOMOTO CO., INC.: EXPANSIONS, JANUARY 2023–JULY 2026 269
TABLE 321 AJINOMOTO CO., INC.: DEALS, JANUARY 2023–JULY 2026 269
TABLE 322 ST PHARM: COMPANY OVERVIEW 270
TABLE 323 ST PHARM: SERVICES OFFERED 271
TABLE 324 ST PHARM: EXPANSIONS, JANUARY 2023–JULY 2026 271
TABLE 325 ST PHARM: DEALS, JANUARY 2023–JULY 2026 271
TABLE 326 KANEKA CORPORATION: COMPANY OVERVIEW 273
TABLE 327 KANEKA CORPORATION: SERVICES OFFERED 275
TABLE 328 POLYPEPTIDE GROUP: COMPANY OVERVIEW 276
TABLE 329 POLYPEPTIDE GROUP: SERVICES OFFERED 277
TABLE 330 POLYPEPTIDE GROUP: EXPANSIONS, JANUARY 2023–JULY 2026 277
TABLE 331 AURIGENE PHARMACEUTICAL SERVICES LTD.: COMPANY OVERVIEW 278
TABLE 332 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED 278
TABLE 333 BIOSPRING: COMPANY OVERVIEW 279
TABLE 334 BIOSPRING: SERVICES OFFERED 279
TABLE 335 BIOSPRING: SERVICE APPROVALS, JANUARY 2023–JULY 2026 280
TABLE 336 BIOSPRING: EXPANSIONS, JANUARY 2023–JULY 2026 280
TABLE 337 NIPPON SHOKUBAI CO., LTD.: COMPANY OVERVIEW 281
TABLE 338 NIPPON SHOKUBAI CO., LTD.: SERVICES OFFERED 282
TABLE 339 NIPPON SHOKUBAI CO., LTD.: SERVICE LAUNCH, JANUARY 2023–JULY 2026 283
TABLE 340 NIPPON SHOKUBAI CO., LTD.: EXPANSIONS, JANUARY 2023–JULY 2026 283
TABLE 341 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW 284
TABLE 342 LGC BIOSEARCH TECHNOLOGIES: SERVICES OFFERED 285
TABLE 343 LGC BIOSEARCH TECHNOLOGIES: SERVICE LAUNCH, JANUARY 2023–JULY 2026 286
TABLE 344 LGC BIOSEARCH TECHNOLOGIES: DEALS, JANUARY 2023–JULY 2026 286
TABLE 345 LGC BIOSEARCH TECHNOLOGIES: EXPANSIONS, JANUARY 2023–JULY 2026 287
TABLE 346 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 306
TABLE 347 RISK ASSESSMENT 307
FIGURE 1 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION AND REGIONS CONSIDERED 33
FIGURE 2 OLIGONUCLEOTIDE CDMO MARKET: YEARS CONSIDERED 34
FIGURE 3 MARKET SCENARIO 36
FIGURE 4 GLOBAL OLIGONUCLEOTIDE CDMO MARKET, 2024–2031 37
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET, 2023–2026 37
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF OLIGONUCLEOTIDE CDMO MARKET 38
FIGURE 7 HIGH-GROWTH SEGMENTS IN OLIGONUCLEOTIDE CDMO MARKET, 2026–2031 39
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN OLIGONUCLEOTIDE CDMO MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 40
FIGURE 9 INCREASING FOCUS ON PRECISION/PERSONALIZED MEDICINE 41
FIGURE 10 ANTISENSE OLIGONUCLEOTIDES ACCOUNTED FOR LARGEST SHARE OF OLIGONUCLEOTIDE CDMO MARKET IN NORTH AMERICA IN 2025 42
FIGURE 11 ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN GLOBAL OLIGONUCLEOTIDE CDMO MARKET DURING FORECAST PERIOD 43
FIGURE 12 CONTRACT MANUFACTURING TO DOMINATE MARKET DURING FORECAST PERIOD 44
FIGURE 13 OLIGONUCLEOTIDE CDMO MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45
FIGURE 14 OLIGONUCLEOTIDE CDMO MARKET: PORTER’S FIVE FORCES ANALYSIS 54
FIGURE 15 VALUE CHAIN ANALYSIS 58
FIGURE 16 OLIGONUCLEOTIDE CDMO MARKET: ECOSYSTEM ANALYSIS 61
FIGURE 17 OLIGONUCLEOTIDE CDMO MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63
FIGURE 18 INVESTMENT AND FUNDING SCENARIO, 2023–2026 (USD MILLION) 64
FIGURE 19 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET 77
FIGURE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE 88
FIGURE 21 KEY BUYING CRITERIA, BY END USER 89
FIGURE 22 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT 149
FIGURE 23 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT 171
FIGURE 24 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, 2021–2025 213
FIGURE 25 OLIGONUCLEOTIDE CDMO MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025 214
FIGURE 26 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2025 217
FIGURE 27 OLIGONUCLEOTIDE CDMO MARKET: COMPANY FOOTPRINT 218
FIGURE 28 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2025 224
FIGURE 29 BRAND/PRODUCT COMPARATIVE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, BY COMPANY 230
FIGURE 30 EV/EBITDA OF KEY VENDORS IN CDMO MARKET 231
FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE CDMO MARKET 231
FIGURE 32 BACHEM INC.: COMPANY SNAPSHOT (2025) 233
FIGURE 33 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 237
FIGURE 34 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 241
FIGURE 35 WUXI APPTEC: COMPANY SNAPSHOT (2025) 245
FIGURE 36 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025) 248
FIGURE 37 LONZA: COMPANY SNAPSHOT (2025) 251
FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 254
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 257
FIGURE 40 GENSCRIPT: COMPANY SNAPSHOT (2025) 260
FIGURE 41 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2025) 263
FIGURE 42 EUROAPI: COMPANY SNAPSHOT (2025) 266
FIGURE 43 AJINOMOTO CO., INC.: COMPANY SNAPSHOT (2025) 268
FIGURE 44 ST PHARM: COMPANY SNAPSHOT (2025) 270
FIGURE 45 KANEKA CORPORATION: COMPANY SNAPSHOT (2025) 274
FIGURE 46 POLYPEPTIDE GROUP: COMPANY SNAPSHOT (2025) 276
FIGURE 47 NIPPON SHOKUBAI CO., LTD.: COMPANY SNAPSHOT (2025) 282
FIGURE 48 LGC BIOSEARCH TECHNOLOGIES: COMPANY SNAPSHOT (2024) 285
FIGURE 49 OLIGONUCLEOTIDE CDMO MARKET: RESEARCH DESIGN 294
FIGURE 50 OLIGONUCLEOTIDE CDMO MARKET: BREAKDOWN OF PRIMARIES 297
FIGURE 51 OLIGONUCLEOTIDE CDMO MARKET: INSIGHTS FROM PRIMARIES 298
FIGURE 52 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025 299
FIGURE 53 OLIGONUCLEOTIDE CDMO MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 300
FIGURE 54 ILLUSTRATIVE EXAMPLE OF AGILENT TECHNOLOGIES, INC.:
REVENUE ANALYSIS (2025) 301
FIGURE 55 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 302
FIGURE 56 OLIGONUCLEOTIDE CDMO MARKET: CAGR PROJECTIONS 304
FIGURE 57 OLIGONUCLEOTIDE CDMO MARKET: DATA TRIANGULATION 305
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們